Brinker Capital Inc. Grows Holdings in Shire (SHPG)

Brinker Capital Inc. boosted its position in shares of Shire (NASDAQ:SHPG) by 12.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,154 shares of the biopharmaceutical company’s stock after purchasing an additional 2,944 shares during the period. Brinker Capital Inc.’s holdings in Shire were worth $4,063,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Bluestein R H & Co. bought a new position in Shire during the 1st quarter worth about $383,000. Lucia Wealth Services LLC boosted its stake in shares of Shire by 93.6% during the 1st quarter. Lucia Wealth Services LLC now owns 19,176 shares of the biopharmaceutical company’s stock worth $2,865,000 after buying an additional 9,270 shares during the last quarter. Seizert Capital Partners LLC boosted its stake in shares of Shire by 20.6% during the 1st quarter. Seizert Capital Partners LLC now owns 12,609 shares of the biopharmaceutical company’s stock worth $1,884,000 after buying an additional 2,151 shares during the last quarter. Sphera Funds Management LTD. boosted its stake in shares of Shire by 127.2% during the 1st quarter. Sphera Funds Management LTD. now owns 196,500 shares of the biopharmaceutical company’s stock worth $29,355,000 after buying an additional 110,000 shares during the last quarter. Finally, Alerus Financial NA boosted its stake in shares of Shire by 11.4% during the 1st quarter. Alerus Financial NA now owns 23,756 shares of the biopharmaceutical company’s stock worth $3,549,000 after buying an additional 2,439 shares during the last quarter. Hedge funds and other institutional investors own 18.12% of the company’s stock.

A number of research firms have recently commented on SHPG. Kepler Capital Markets restated a “buy” rating on shares of Shire in a research note on Friday, May 11th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research note on Tuesday, May 8th. ValuEngine downgraded shares of Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. BTIG Research restated a “buy” rating and set a $195.00 price objective on shares of Shire in a research note on Sunday, April 29th. Finally, SunTrust Banks reduced their price objective on shares of Shire to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Shire presently has an average rating of “Buy” and a consensus price target of $201.64.

Shares of NASDAQ:SHPG opened at $164.50 on Friday. Shire has a 52-week low of $123.73 and a 52-week high of $185.34. The stock has a market capitalization of $51.64 billion, a P/E ratio of 10.86, a PEG ratio of 1.34 and a beta of 1.30. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.14 and a quick ratio of 0.66.

Shire (NASDAQ:SHPG) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.28. Shire had a net margin of 28.96% and a return on equity of 13.60%. The business had revenue of $3.77 billion during the quarter. During the same quarter last year, the business posted $3.63 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. sell-side analysts expect that Shire will post 15.26 EPS for the current year.

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply